POSEIDA THERAPEUTICS INC (PSTX)
US73730P1084 - Common Stock
Which stocks are experiencing notable movement on Tuesday?
Which stocks are experiencing notable movement on Tuesday?
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CTV, AUB on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Which stocks are moving before the opening bell on Tuesday?
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing...
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target Cash flow...
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
MaxCyte Appoints Cynthia Collins to its Board of Directors
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had...
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics to Present at Upcoming Investor Conferences
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024
PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Poseida Therapeutics (NASDAQ:PSTX) just reported results for the second quarter...
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
Continued Roche CAR-T partnership progress with agreement for Poseida to initiate Phase 1b portion of P-BCMA-ALLO1 clinical trial Strong Astellas research...
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated...
PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024
PSTX stock results show that Poseida Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
PSTX Stock Earnings: Poseida Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Poseida Therapeutics (NASDAQ:PSTX) just reported results for the first quarter ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO:...
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...